申请人:Fujisawa Pharmaceutical Company, Ltd.
公开号:US04349552A1
公开(公告)日:1982-09-14
A compound of the formula: ##STR1## wherein R is a bridged alicyclic group selected from the group consisting of norbornyl, norbornenyl, bicyclo[2,2,2]-heptyl and adamantyl optionally substituted by at least one substituent selected from the group consisting of lower alkyl, carboxy, lower alkoxycarbonyl, alkylidenedioxy, N,N-di(lower)alkylcarbamoyl, amino, loweralkoxycarbonylamino and halogen. The present compound is useful in the therapeutic treatment of cancer in human beings and animals.
一种化合物的化学式为:##STR1##其中R是从诺伯尼尔、诺伯烯基、双环[2,2,2]-庚基和金刚烷基中选择的桥环脂环基,可选择地被来自较低烷基、羧基、较低烷氧羰基、烷基二氧基、N,N-双(较低)烷基氨基甲酰、氨基、较低烷氧羰胺基和卤素的至少一种取代基取代。该化合物可用于治疗人类和动物的癌症。